Gilead Sciences stock weighs Livdelzi data against regulatory hurdles
Published on 11/06/2026 at 14:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLivdelzi Data and Regulatory Path
- Gilead reported strong Phase 3 IDEAL results in patients with primary biliary cholangitis and lower alkaline phosphatase levels.
- The company plans discussions with global regulators, while the data will be presented at The Liver Meeting in Denver.
- Livdelzi already has accelerated approval in the United States, so broader use depends on regulatory review and confirmatory evidence.
Gilead Sciences reported positive Phase 3 results for Livdelzi in a patient group with primary biliary cholangitis, sharpening the drug's potential beyond its current treatment population. The company said on Thursday, November 5, that it will engage global regulatory authorities based on the IDEAL study results.
At Week 52, 75.4 percent of participants receiving Livdelzi reached the study's composite alkaline phosphatase normalization endpoint, compared with 16.1 percent on placebo. The endpoint required alkaline phosphatase at or below the upper limit of normal and at least a 15 percent reduction from baseline. Gilead published the results in its Gilead Sciences investor release.
Trial Targets Underserved Patients
IDEAL enrolled 96 adults with primary biliary cholangitis whose alkaline phosphatase levels were above normal but below 1.67 times the upper limit of normal. Participants either had inadequate control despite 12 months of ursodeoxycholic acid treatment or could not tolerate that therapy. Gilead described IDEAL as the first trial to evaluate Livdelzi in this lower-elevation population, which has largely been excluded from earlier pivotal studies of second-line treatments.
The treatment effect appeared early: 52.3 percent of Livdelzi participants reached the composite endpoint after one month, versus 6.5 percent in the placebo group, and the response continued through Week 52. Gilead said the safety profile was consistent with earlier Livdelzi studies. Serious adverse events occurred in 3.1 percent of participants on Livdelzi and 12.9 percent on placebo, with none considered related to the trial drug.
Regulatory Review Remains Next Catalyst
The findings will be presented at The Liver Meeting 2026, hosted by the American Association for the Study of Liver Diseases in Denver from November 5 to 9. The results have also been accepted for upcoming publication in the Journal of Hepatology. Gilead's next step is regulatory discussion rather than an immediate label expansion, leaving the timing and scope of any broader authorization open.
Livdelzi currently has U.S. accelerated approval for primary biliary cholangitis in combination with ursodeoxycholic acid for adults with an inadequate response, or as monotherapy for patients unable to tolerate that treatment. Gilead's release states that continued approval may depend on confirmatory evidence because survival improvement or prevention of liver decompensation has not been demonstrated.
Gilead Sciences stock traded at 147.08 euros on Lang & Schwarz at 2:00 p.m. CET on Friday, November 6, 2026, 3.93 percent below the Xetra close of Thursday, November 5. Yahoo Finance lists the Xetra close at 153.10 euros for November 5, 2026. Investors can follow the real-time quote of Gilead Sciences stock.
Gilead Sciences stock at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Home exchange: Nasdaq
- Lang & Schwarz quote: 147.08 euros at 2:00 p.m. CET on November 6, 2026
- Xetra close: 153.10 euros on November 5, 2026
- Daily difference: 3.93 percent below the Xetra close
The S&P 500 sets the broader US market backdrop for Gilead Sciences stock.
Further developments depend on Gilead's regulatory discussions, the presentation at The Liver Meeting and subsequent publication of the IDEAL findings. More news and analyses on Gilead Sciences stock.
